What is the recommended management for a hospice patient on lorazepam (Ativan) for anxiety or agitation?

Management of Lorazepam in Hospice Patients

Lorazepam 0.5-1 mg orally four times daily as needed (maximum 4 mg/24 hours) is the guideline-recommended first-line treatment for anxiety or agitation in hospice patients who can swallow, with reduced doses of 0.25-0.5 mg (maximum 2 mg/24 hours) for elderly or debilitated patients. 1

Dosing and Administration

For Patients Able to Swallow

• Standard dosing: Lorazepam 0.5-1 mg orally every 4-6 hours as needed, maximum 4 mg in 24 hours 1, 2
• Elderly/debilitated patients: Reduce dose to 0.25-0.5 mg, maximum 2 mg in 24 hours 1, 2
• Alternative route: Oral tablets can be used sublingually (off-label) for patients with mild swallowing difficulties 1, 2
• Liquid formulation: Lorazepam oral concentrate (2 mg/mL) is available for those requiring liquid medications 2

For Patients Unable to Swallow

• Switch to midazolam: 2.5-5 mg subcutaneously every 2-4 hours as needed 1
• Continuous infusion: If needed more than twice daily, consider subcutaneous infusion via syringe driver starting with midazolam 10 mg over 24 hours 1
• Renal adjustment: Reduce dose to 5 mg over 24 hours if eGFR <30 mL/min 1

When Lorazepam is Appropriate vs. When to Use Alternatives

Use Lorazepam as First-Line For:

• Primary anxiety or agitation without delirium 1, 3
• Refractory agitation despite high-dose neuroleptics in delirium 1
• Combination therapy: Adding lorazepam 0.5-2 mg every 4-6 hours when agitation persists despite adequate haloperidol dosing 1, 4

Use Haloperidol Instead For:

• Delirium with agitation: Haloperidol 0.5-1 mg orally at night and every 2 hours as needed is the preferred first-line agent 1, 4
• Maximum haloperidol dose: 10 mg daily (5 mg daily in elderly patients) 1
• Alternative antipsychotics if haloperidol ineffective: risperidone 0.5-1 mg twice daily, olanzapine 2.5-15 mg daily, or quetiapine 50-100 mg twice daily 1, 4

Critical Safety Considerations

Address Reversible Causes First

Before initiating or escalating lorazepam, always evaluate and treat:

• Metabolic causes, hypoxia, urinary retention, constipation, bowel obstruction 1, 3
• Medication effects or withdrawal (opioids, anticholinergics, benzodiazepines themselves) 1
• Non-pharmacological interventions: Explore patient concerns, ensure effective communication and orientation, provide adequate lighting, orient with family presence 1, 3, 4

High-Risk Drug Interactions

• Opioid combination: Concomitant use with opioids significantly increases risk of respiratory depression and sedation; this combination requires careful monitoring despite being common in hospice 5
• Respiratory compromise: Use with extreme caution in patients with COPD or sleep apnea 5

Common Adverse Effects

• Sedation (15.9%), dizziness (6.9%), weakness (4.2%), unsteadiness (3.4%) increase with age 5
• Respiratory depression and apnea are dose-dependent, particularly concerning when combined with opioids 5
• Paradoxical reactions (anxiety, agitation, hostility) may occur, especially in elderly patients; discontinue if these develop 5

Evidence from Clinical Practice

Real-World Hospice Use

• 70% of palliative care patients receive benzodiazepines, with lorazepam most commonly prescribed for anxiety and agitation 6
• Low administration rates: In home hospice, only 17% of prescribed lorazepam doses are administered on admission and 27% on day of death, suggesting caregivers may need more guidance on when to administer PRN medications 7
• Discontinuation near death: 96% of patients do not receive antidepressants/anxiolytics on day of death due to difficulty swallowing, minimal consciousness, or patient refusal 8

Efficacy Data

• Combination therapy superior: In advanced cancer patients with agitated delirium, lorazepam 3 mg IV plus haloperidol 2 mg IV resulted in significantly greater reduction in agitation at 8 hours (-4.1 points vs -2.3 points on RASS scale) compared to haloperidol alone 9
• Reduced rescue medication needs: The combination required less rescue neuroleptics (median 2 mg vs 4 mg) and was perceived as more comfortable by both caregivers (84% vs 37%) and nurses (77% vs 30%) 9

Practical Algorithm for Hospice Management

Step 1: Assess if symptom is primarily anxiety/agitation or delirium-related

• Pure anxiety/agitation → Start lorazepam 0.5-1 mg PO q4-6h PRN (0.25-0.5 mg in elderly) 1
• Delirium with agitation → Start haloperidol 0.5-1 mg PO q2h PRN 1, 4

Step 2: If haloperidol alone insufficient for delirium-related agitation

• Add lorazepam 0.5-2 mg every 4-6 hours to haloperidol regimen 1, 4

Step 3: If patient cannot swallow

• Switch to midazolam 2.5-5 mg SC q2-4h PRN 1
• Consider continuous infusion if needed >2 times daily 1

Step 4: Monitor and titrate

• Titrate to optimal effect while monitoring for sedation and respiratory depression 1, 4
• Reduce doses in hepatic or renal failure 1

Important Caveats

• FDA indication: Lorazepam is FDA-approved only for short-term anxiety management (up to 4 months), though hospice use for symptom control at end of life is standard practice 5
• Scheduled vs PRN: Most hospice patients (92.8%) receive PRN-only regimens, placing decision-making burden on caregivers who may need more support 7
• Terminal sedation: Only 3-16% of hospice patients receive deep continuous sedation with benzodiazepines; most use is for intermittent symptom control 6, 10
• Avoid abrupt discontinuation: If patient has been on lorazepam for extended period, do not abruptly stop even in final days as withdrawal can occur; taper if discontinuation needed 5